Structure elucidation capabilities on typical pharmaceutical drugs by new nuclear magnetic resonance technology: a 400 MHz high-temperature superconducting power-driven magnet NMR system

被引:6
作者
Elipe, Maria Victoria Silva [1 ]
Donovan, Neil [2 ]
Krull, Robert [2 ]
Pooke, Donald [3 ]
Colson, Kimberly L. [2 ]
机构
[1] Amgen Inc, Dept Attribute Sci, One Amgen Ctr Dr, Thousand Oaks, CA 91320 USA
[2] Bruker BioSpin, Billerica, MA USA
[3] HTS 110, Lower Hutt, New Zealand
关键词
Correlation spectroscopy (COSY); heteronuclear multiple bond coherence (HMBC); heteronuclear single quantum coherence (HSQC); high-temperature superconducting (HTS) power-driven magnet; nuclear magnetic resonance (NMR); nuclear Overhauser effect spectroscopy (NOESY); selective excitation; CINACALCET;
D O I
10.1080/10739149.2018.1516226
中图分类号
O65 [分析化学];
学科分类号
070302 ; 081704 ;
摘要
Nuclear magnetic resonance (NMR) is a powerful technique for the structure elucidation of organic molecules and significantly important in the pharmaceutical industry supporting the discovery and development of drug substances or active pharmaceutical ingredients (APIs). Following an initial study and assessment of a prototype NMR instrument with a high-temperature superconducting (HTS) power-driven magnet of 9.4 T (400 MHz for H-1 observation) operating with standard commercial electronics and probes, we tested the instrument with three compounds representing typical pharmaceutical drugs. We compared results from two probes and shimstacks with different geometries (broadband fluorine observe (BBFO) with Bruker orthogonal shim system-3 (BOSS3) and Bruker quattro nucleus probe (QNP) with BOSS1 shims) testing standard one-dimensional (1D) NMR experiments including selective excitation experiments, and two-dimensional (2D) homonuclear and heteronuclear experiments for the purposes of evaluating the equipment for structure elucidation capabilities. In our initial study on cinacalcet HCl, only the 1D H-1 experiment showed a loss of resolution when using the longer coiled BBFO probe with the BOSS3 shims compared to the shorter coiled QNP probe with BOSS1 shims. The selective excitation experiments using the cinacalcet HCl were successful. Our characterization of 1D (H-1, C-13, F-19) and 2D (H-1-H-1 and H-1-C-13) NMR experiments for compounds I and II with the two probes and shimstacks indicated no significance differences. Overall, these results are satisfactory with the HTS magnet at the field of 9.4 T for the structural elucidation work of standard pharmaceutical compounds. This new technology has the advantage of being able to locate the HTS NMR magnet system in any chemistry or analytical laboratory where the samples are produced, facilitating rapid analysis with minor needs from the facilities and without cryogenic liquids.
引用
收藏
页码:195 / 212
页数:18
相关论文
共 16 条
[1]   Cinacalcet hydrochloride [J].
Balfour, JAB ;
Scott, LJ .
DRUGS, 2005, 65 (02) :271-281
[2]   Application of twin screw extrusion to the manufacture of cocrystals: scale-up of AMG 517-sorbic acid cocrystal production [J].
Daurio, Dominick ;
Nagapudi, Karthik ;
Li, Lan ;
Quan, Peter ;
Nunez, Fernando-Alvarez .
FARADAY DISCUSSIONS, 2014, 170 :235-249
[3]   Cinacalcet HCI: a novel therapeutic for hyperparathyroid [J].
de Francisco, ALM .
EXPERT OPINION ON PHARMACOTHERAPY, 2005, 6 (03) :441-452
[4]   Novel vanilloid receptor-1 antagonists: 2. Structure-activity relationships of 4-oxopyrimidines leading to the selection of a clinical candidate [J].
Doherty, Elizabeth M. ;
Fotsch, Christopher ;
Bannon, Anthony W. ;
Bo, Yunxin ;
Chen, Ning ;
Dominguez, Celia ;
Falsey, James ;
Gavva, Narender R. ;
Katon, Jodie ;
Nixey, Thomas ;
Ognyanov, Vassil I. ;
Pettus, Liping ;
Rzasa, Robert M. ;
Stec, Markian ;
Surapaneni, Sekhar ;
Tamir, Rami ;
Zhu, Jiawang ;
Treanor, James J. S. ;
Norman, Mark H. .
JOURNAL OF MEDICINAL CHEMISTRY, 2007, 50 (15) :3515-3527
[5]   Cinacalcet: An oral calcimimetic agent for the management of hyperparathyroidism [J].
Dong, BJ .
CLINICAL THERAPEUTICS, 2005, 27 (11) :1725-1751
[6]   Performance of new 400-MHz HTS power-driven magnet NMR technology on typical pharmaceutical API, cinacalcet HCl [J].
Elipe, Maria Victoria Silva ;
Donovan, Neil ;
Krull, Robert ;
Pooke, Donald ;
Colson, Kimberly L. .
MAGNETIC RESONANCE IN CHEMISTRY, 2018, 56 (09) :817-825
[7]   AMG 837: A potent, orally bioavailable GPR40 agonist [J].
Houze, Jonathan B. ;
Zhu, Liusheng ;
Sun, Ying ;
Akerman, Michelle ;
Qiu, Wei ;
Zhang, Alex J. ;
Sharma, Rajiv ;
Schmitt, Michael ;
Wang, Yingcai ;
Liu, Jiwen ;
Liu, Jingian ;
Medina, Julio C. ;
Reagan, Jeff D. ;
Luo, Jian ;
Tonn, George ;
Zhang, Jane ;
Lu, Jenny Ying-Lin ;
Chen, Michael ;
Lopez, Edwin ;
Nguyen, Kathy ;
Yang, Li ;
Tang, Liang ;
Tian, Hui ;
Shuttleworth, Steven J. ;
Lin, Daniel C. -H. .
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2012, 22 (02) :1267-1270
[8]  
Iqbal J, 2003, IDRUGS, V6, P587
[9]  
Kuriyama T., 1990, Adv. Cryog. Eng, P1261, DOI [10.1007/978-1-4613-0639-9_150, DOI 10.1007/978-1-4613-0639-9_150]
[10]   Analgesic potential of TRPV1 antagonists [J].
Kym, Philip R. ;
Kort, Michael E. ;
Hutchins, Charles W. .
BIOCHEMICAL PHARMACOLOGY, 2009, 78 (03) :211-216